Literature DB >> 16741180

Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes.

Sophia Wang1, Sun-Ryung Lee, Shu-Zhen Guo, Woo Jean Kim, Joan Montaner, Xiaoying Wang, Eng H Lo.   

Abstract

BACKGROUND AND
PURPOSE: Hemorrhagic conversion after tissue plasminogen activator (tPA) stroke therapy has been linked with elevations in matrix metalloproteinase-9 (MMP-9) at the neurovascular interface. Here, we test the idea that statins may directly ameliorate tPA-induced MMP-9 dysregulation.
METHODS: Recombinant human tPA (5 microg/mL) was added to primary rat cortical astrocytes. Zymography was used to quantify MMP-9 levels in conditioned media. Effects of simvastatin or the Rho kinase inhibitor Y-27632 were assessed by pretreating cells before tPA exposure.
RESULTS: Simvastatin (1 to 10 micromol/L) significantly reduced tPA-induced MMP-9 in cortical astrocytes. This effect may be mediated via the Rho kinase pathway because tPA-induced activation of Rho signaling was suppressed by simvastatin, and tPA-induced MMP-9 levels were similarly reduced by the Rho kinase inhibitor Y-27632 (1 to 10 micromol/L).
CONCLUSIONS: Statins reduce tPA-induced MMP-9 dysregulation by inhibiting the Rho signaling pathway. Statins may ameliorate tPA-associated MMP imbalances in stroke.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741180     DOI: 10.1161/01.STR.0000226923.48905.39

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  23 in total

Review 1.  The neurovascular unit and combination treatment strategies for stroke.

Authors:  Li Zhang; Zheng Gang Zhang; Michael Chopp
Journal:  Trends Pharmacol Sci       Date:  2012-05-16       Impact factor: 14.819

2.  Molecular contributions to neurovascular unit dysfunctions after brain injuries: lessons for target-specific drug development.

Authors:  Amandine Jullienne; Jérôme Badaut
Journal:  Future Neurol       Date:  2013-11-01

3.  Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke.

Authors:  Ran Liu; Qing Liu; Shaoqing He; James W Simpkins; Shao-Hua Yang
Journal:  J Pharmacol Exp Ther       Date:  2009-12-01       Impact factor: 4.030

Review 4.  Tissue-type plasminogen activator as a therapeutic target in stroke.

Authors:  Iordanis Gravanis; Stella E Tsirka
Journal:  Expert Opin Ther Targets       Date:  2008-02       Impact factor: 6.902

5.  Tissue plasminogen activator enhances the hypoxia/reoxygenation-induced impairment of the blood-brain barrier in a primary culture of rat brain endothelial cells.

Authors:  Takeshi Hiu; Sinsuke Nakagawa; Kentaro Hayashi; Naoki Kitagawa; Keisuke Tsutsumi; Junichi Kawakubo; Masaru Honda; Kazuhiko Suyama; Izumi Nagata; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2008-07-16       Impact factor: 5.046

6.  Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice.

Authors:  Monica Garcia-Alloza; Claudia Prada; Carli Lattarulo; Sara Fine; Laura A Borrelli; Rebecca Betensky; Steven M Greenberg; Matthew P Frosch; Brian J Bacskai
Journal:  J Neurochem       Date:  2009-04-08       Impact factor: 5.372

7.  Lipid profile, statin use, and outcome after intravenous thrombolysis for acute ischaemic stroke.

Authors:  M Uyttenboogaart; M W Koch; K Koopman; P C Vroomen; G J Luijckx; J De Keyser
Journal:  J Neurol       Date:  2008-03-14       Impact factor: 4.849

8.  Activation of protein tyrosine kinases and matrix metalloproteinases causes blood-brain barrier injury: Novel mechanism for neurodegeneration associated with alcohol abuse.

Authors:  James Haorah; Kathy Schall; Servio H Ramirez; Yuri Persidsky
Journal:  Glia       Date:  2008-01-01       Impact factor: 7.452

9.  Normobaric hyperoxia reduces the neurovascular complications associated with delayed tissue plasminogen activator treatment in a rat model of focal cerebral ischemia.

Authors:  Wenlan Liu; Jill Hendren; Xu-Jun Qin; Ke Jian Liu
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

Review 10.  Plasmin-dependent modulation of the blood-brain barrier: a major consideration during tPA-induced thrombolysis?

Authors:  Be'eri Niego; Robert L Medcalf
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-04       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.